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Abstract
Excess vitamin A has been associated with decreased cortical bone thickness and 
increased fracture risk. While most studies in rodents have employed high dosages of 
vitamin A for short periods of time, we investigated the bone phenotype in mice after 
longer exposure to more clinically relevant doses. For 1, 4 and 10 weeks, mice were 
fed a control diet (4.5 µg retinyl acetate/g chow), a diet modeled from the human 
upper tolerable limit (UTL; 20 µg retinyl acetate/g chow) and a diet three times UTL 
(supplemented; 60 µg retinyl acetate/g chow). Time-dependent decreases in periosteal 
circumference and bone mineral content were noted with the supplemented dose. 
These reductions in cortical bone resulted in a significant time-dependent decrease 
of predicted strength and a non-significant trend toward reduced bone strength as 
analyzed by three-point bending. Trabecular bone in tibiae and vertebrae remained 
unaffected when vitamin A was increased in the diet. Dynamic histomorphometry 
demonstrated that bone formation was substantially decreased after 1 week of 
treatment at the periosteal site with the supplemental dose. Increasing amount of 
vitamin A decreased endocortical circumference, resulting in decreased marrow area, 
a response associated with enhanced endocortical bone formation. In the presence of 
bisphosphonate, vitamin A had no effect on cortical bone, suggesting that osteoclasts 
are important, even if effects on bone resorption were not detected by osteoclast 
counting, genes in cortical bone or analysis of serum TRAP5b and CTX. In conclusion, our 
results indicate that even clinically relevant doses of vitamin A have a negative impact 
on the amount of cortical bone.
Introduction
Vitamin A is an essential nutrient consumed in the diet in 
the form of retinyl esters or beta carotene. Retinyl esters 
are transported by chylomicrons to the liver where they 
are converted to retinol and bound to retinol-binding 
protein and released into the blood stream. In target 
cells, retinol is converted to all-trans retinoic acid (ATRA), 
which is the hormonally active form of vitamin A. 
ATRA binds to cellular retinoic acid-binding protein and 
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translocates to the nucleus where it ligates primarily to 
retinoic acid receptors, regulating gene transcription 
(reviewed in Tata 2002, Conaway et  al. 2013, Henning 
et al. 2015, Green et al. 2016). ATRA can also diffuse to 
adjacent cells and have paracrine effects and acts as an 
important morphogen during embryonic development 
(Kam et al. 2012). Vitamin A plays a crucial role in various 
physiological functions, including immune system 
regulation, vision and cell growth and differentiation 
(reviewed in Wiseman et al. 2017).
In humans, increased vitamin A consumption and 
elevated serum retinol levels have been associated with 
increased bone fragility and fracture risk (Melhus et  al. 
1998, Whiting & Lemke 1999, Feskanich et  al. 2002, 
Michaelsson et  al. 2003), suggesting that increased 
intake of vitamin A may be a risk factor for secondary 
osteoporosis. Although not all studies have consistently 
demonstrated the negative relationship between vitamin A 
and bone mass (for review see Conaway et al. 2013), a meta-
analysis has shown that increased intake of vitamin A 
and elevated blood levels of retinol are associated with an 
increased risk of hip fracture (Wu et al. 2014). Interestingly, 
a dose–response analysis revealed that decreased levels of 
retinol also increased the risk of hip fracture (Wu et  al. 
2014).
Rodent studies have also shown detrimental effects 
of vitamin A on the skeleton. Rapid induction of 
hypervitaminosis A, either by feeding or by injecting 
retinoids, induces cortical bone loss in long bones of rats 
(Trechsel et al. 1987, Hough et al. 1988, Johansson et al. 
2002, Kneissel et al. 2005, Lind et al. 2011, 2013, Wray et al. 
2011) and mice (Kneissel et al. 2005), which is associated 
with decreased bone strength (Johansson et al. 2002, Lind 
et  al. 2011). This reduction in the amount of cortical 
bone has been attributed to an increase in the number 
of periosteal osteoclasts (Trechsel et al. 1987, Hough et al. 
1988, Kneissel et al. 2005, Lind et al. 2011). In trabecular 
bone, there have been fewer studies investigating the effects 
of vitamin A and the results have been inconsistent. In 
two studies, trabecular bone mineral density in the femur 
and the tibia was decreased by increased vitamin A intake 
(Lind et al. 2011, Wray et al. 2011), whereas in three other 
studies no effects on the trabecular bone mineral density 
of the humerus or tibia were observed (Johansson et  al. 
2002, Kneissel et al. 2005, Green et al. 2015). In the only 
study investigating the effect of increased dietary retinol 
on trabecular bone mass in vertebrae, it was found that 
vitamin A decreased bone mass, an effect associated with 
both an increased number of osteoclasts and a decreased 
number of osteoblasts (Yorgan et al. 2016).
Although numerous investigations have shown either 
stimulatory or inhibitory effects of vitamin A on osteoblast 
differentiation and function in vitro (reviewed in Conaway 
et  al. 2013, Green et  al. 2016), very few studies have 
analyzed effects of vitamin A on bone formation in vivo. 
Kneissel et al. and Lind et al. found that hypervitaminosis 
A decreased mineralizing surfaces on the periosteal side of 
cortical bone in the femur and tibia (Kneissel et al. 2005, 
Lind et  al. 2013); however, mineralizing apposition rate 
was inhibited in one of these studies (Lind et al. 2013), but 
unaffected in the other (Kneissel et al. 2005).
The current recommended daily allowance (RDA) 
of vitamin A in adults is 900 and 700 µg retinol activity 
equivalents per day in males and females, respectively, 
while the UTL is 3000 µg/day (Trumbo et al. 2001). With 
over one-third of the population in the USA taking 
dietary supplements (Bailey et al. 2011), excess vitamin A 
consumption/hypervitaminosis A is a potential health risk.
Although rodent studies have provided insight into 
changes in cortical bone caused by hypervitaminosis A, 
the doses (13 to at least 142 times higher than the 
human RDA diet) and the short durations (7–14 days) of 
the experiments are questionable reflections of human 
consumption. For this reason, the present study was 
designed to investigate the effects of lower, more clinically 
relevant dosages of vitamin A (4.5–13 times higher 
modeled from the human RDA) on bone phenotype in 
mice after longer exposure (1–10 weeks). We assessed in 
detail not only the effects of vitamin A on the amount of 
cortical bone, but also vitamin A’s effects on trabecular 
bone in long bones as well as in vertebra, paying special 
attention to osteoclastic bone resorption and osteoblastic 
bone formation.
Materials and methods
Animals and study design
All animal experimental procedures were approved by 
the Ethics Committee at the University of Gothenburg 
and carried out in accordance to relevant guidelines. 
C57BL/6 female mice (Harlan Laboratories, Inc.; Taconic 
Bioscience) were received at 7–8  weeks of age and 
acclimatized for 1  week. C57BL6/J mice of 9–19  weeks, 
as used in this experiment, are sexually mature at the 
start of the experiments and growing less rapidly than 
mice aged 5–8  weeks. Mice were housed in groups of 
five at 22°C with a 12:12 h light–darkness cycle and fed 
diets (Harlan Laboratories Inc.) containing either 4.5 µg 
retinyl acetate/g chow (control (Harlan 2016) repelleted), 
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0316
http://joe.endocrinology-journals.org © 2018 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 11/28/2018 12:21:59AM
via Australian National University
391
Research
V Lionikaite et al. Vitamin A decreases cortical 
bone
239:3Journal of 
Endocrinology
20 µg retinyl acetate/g chow (upper tolerable level; UTL) 
or 60 µg retinyl acetate/g chow (supplemented) ad libitum 
for 4 (n = 15/group) or 10 weeks (n = 10/group). By using 
a 4.5- and 13-fold increased concentrations of retinyl 
acetate in the chow, we aimed to mimic the fold increase 
for upper tolerable and supplemented levels in humans 
calculated from the RDA. An additional 8-day experiment 
with three groups was performed, feeding 8- to 9-week-
old mice control, supplemented or hypervitaminosis A 
diet (Hypervit A; 450 µg retinyl acetate/g chow, 
n = 10/group).
A separate bisphosphonate experiment was performed 
on 8- to 9-week-old mice pre-treated with intraperitoneal 
(i.p.) injections of 200 µL zoledronic acid (ZA; 200 µg/kg; 
0.02 µg/µL; Frasenius Kabi AB, Uppsala, Sweden) or vehicle 
(saline) twice/week for 2 weeks (n = 10/group) (de Molon 
et  al. 2015). They were then fed control (4.5 µg retinyl 
acetate/g chow) or supplemented (60 µg retinyl acetate/g 
chow) vitamin A diets and the twice/week injections of 
ZA continued for 4 weeks.
Body weights were monitored throughout all 
experiments (Supplementary Fig.  1, see section on 
supplementary data given at the end of this article). At the 
termination of all experiments, mice were anesthetized 
with Ketador/Dexdomitor cocktail. Blood was collected 
from the subclavian artery. Serum was aliquoted and 
stored at −80°C till further use. Mice were terminated 
via cervical dislocation. Liver was dissected and weighed. 
Vertebra (L3–L6), femurs and tibias were dissected, fixed 
in formalin for 3  days and stored in ethanol for later 
analysis.
The predesigned primary endpoints were to record 
the effect of vitamin A diets on cortical and trabecular 
bone mass. All assessments of the outcomes were done 
in total blinding of the investigators. Power analysis 
suggested that we needed at least eight mice per group to 
detect biologically significant effects.
Serum analyses
Serum retinol and retinyl ester (RE) analysis was carried 
out by Vital Analytical Services (Oslo, Norway) using 
high-performance liquid chromatography. Serum 
tartrate-resistant acid phosphatase (TRAP), C-terminal 
type I collagen (CTX) and osteocalcin (OCN) were 
measured using the MouseTRAP (TRAcP 5b) ELISA 
kit (Immunodiagnostic System), RatLaps (CTX-I) EIA 
ELISA kit (Immunodiagnostic System) and Osteocalcin 
ELISA kit (Immutopics, Inc.), respectively, following 
manufacturer’s instructions.
Quantitative PCR
The vertebral body of the L3 and L6 (trabecular bone) and 
the flushed mid-diaphyseal tibias (cortical bone) were stored 
at −80°C in RNAlater post killing. RNA was extracted using 
TRIzol reagent (Life Technologies) followed by the RNeasy 
mini kit (Qiagen). Single-strand cDNA was synthesized 
using a High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems). Quantitative real-time PCR (qPCR) 
analyses were performed by using predesigned Taqman 
Assays and Taqman Fast Advance Master Mix (Applied 
Biosystems). The following predesigned real-time PCR 
assays were used for gene expression analysis: Acp5 (Trap; 
Mm00475698_m1), Ctsk (Mm00484036_m1), Tnfsf11 
(Rankl; Mm00441908_m1), Alpl (Alp; Mm00475834_m1), 
Tnfrs11a (Rank; Mm00437135_m1), Tnfrsf11b (Opg; 
Mm0043545_m1), Bglap (Osteocalcin; Mm01741771_g1), 
Col1α1 (Mm00801666_g1), Runx2 (Mm00501580_m1), 
Sp7 (Osterix; Mm04209856_m1) (Applied Biosystems). 
The house-keeping gene 18S was used as the endogenous 
control in all analyses. Data are displayed as fold change 
relative to control.
Assessment of bone parameters
Peripheral quantitative computed tomography 
(pQCT) and microcomputed tomography (µCT)
Peripheral quantitative computed tomography (pQCT) 
was run on the femur and tibia with the pQCT XCT 
RESEARCH M (version 4.5B; Norland). The voxel size 
was 70 µm isotropically. The growth plate was located by 
a scout scan, and the boundary of the metaphysis and 
growth plate was used as a reference point for trabecular 
and cortical scans. Trabecular bone mineral density 
(Tb.BMD) was determined with a single metaphyseal scan 
of the proximal tibia, at a distance 2.6% of the total tibia 
bone length distal from the growth plate, or of the distal 
femur, corresponding to a distance 3% of the total femur 
bone length proximal from the growth plate. Trabecular 
bone region was defined as the inner 45% of the total cross-
sectional area to avoid contamination with cortical bone. 
Cortical bone parameters were analyzed by a single scan 
in the approximate mid-diaphyseal region of the tibia, at a 
distance 30% of the total tibia bone length distal from the 
proximal growth plate or of the femur, at a distance 36% 
of the total femur bone length proximal from the distal 
growth plate. Cortical bone mineral content is presented 
as mg/mm bone length calculated from the diaphyseal 
scan. Cortical thickness was determined by the software 
(Stratec XCT, Research M pQCT v. 6.20C) as the average 
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thickness using a circular model with the threshold set to 
710 mg/cm3. Bone length was measured using a caliper. 
Microcomputed tomography (µCT) analysis was 
performed on the vertebra (L5) using the Skyscan 1072 
scanner (Bruker MicroCT, Aartselaar, Belgium) and imaged 
with an X-ray tube voltage of 50 kV and current of 201 µA 
with an 0.5 mm aluminum filter. Transverse scanning 
angular rotation was 180° and the angular increment of 
0.70°. The voxel size was 13.5 µm isotropically. The NRecon 
software (Burker) was used for image reconstruction 
following established guidelines (Bouxsein et al. 2010).
Histomorphometry and measurement of mechanical 
strength
For the measure of dynamic bone parameters, mice were 
injected (i.p.) with 100 µL of calcein (50 mg/kg) 8 and 
1  day before termination. The whole femurs were fixed 
in 4% paraformaldehyde, followed by dehydration in 
70% ethanol and embedded in methyl meta-acrylate. 
Twenty-five micrometer transverse sections of cortical 
bone from the approximate mid-diaphyseal region were 
cut and periosteal and endocortical mineralized surface 
/bone surface (MS/BS), mineral apposition rate (MAR) and 
bone formation rate/bone surface (BFR/BS) were analyzed.
For static cellular bone parameters, femurs were 
fixed in 4% phosphate-buffered paraformaldehyde, 
decalcified in 10% EDTA in Tris-buffer pH 6.95 and 
embedded in paraffin. Coronal sections were stained 
with heamatotoxylin and TRAP-positive osteoclasts were 
detected by the Naphol AS-BI method. Trabecular bone 
osteoclasts were assessed at the distal and proximal femur 
in the metaphyseal area, not including osteoclasts near 
the growth plate. Cortical bone osteoclasts were counted 
in the diaphysis, excluding the metaphysis.
Histological measurements of marrow area (Ma.Ar), 
total area (Tt.Ar) and cortical bone area (Ct.Ar) were acquired 
from sections used for dynamic histomorphometry.
All parameters (dynamic and static) were measured 
using the Osteomeasure Histomorphometry System 
(OsteoMetrics) following the guidelines of the American 
Society for Bone and Mineral Research (Dempster 
et al. 2013).
Mechanical strength was assessed in the tibias from 
10-week control and supplemented vitamin A mice 
using the three-point bending test. Supports were placed 
±2.75–2.8 mm from 50% of the total length of the bone, 
totaling the span length of 5.5 mm. Tests were performed 
at a loading speed of 0.155 mm/s with a mechanical 
testing machine (Instron 3366, Instron) at mid-tibia, with 
the press head loaded on the medial side. Results were 
calculated with custom-made Excel macros based on the 
computer recorded load deformation raw data curves 
before the first point of permanent deformation, produced 
by Bluehill 2 software v2.6 (Insitron). From the raw 
data curves, the F(max) is the maximum loading force 
(N) applied till breaking, and stiffness (N/mm) was the 
slope of the load deformation curve.
Statistical analyses
Figures and tables are presented as mean ± standard error of 
the mean (s.e.m.). D’Agostino-Pearson omnibus normality 
test was used to assess normality of data and equal variance 
was assumed. Student’s t-test and one-way ANOVA with 
Dunnett’s post hoc test were used to analyze treatment 
effect. Two-way ANOVA for interaction was used to study 
the time-dependent effect of vitamin A treatment and 
the result of ZA treatment. No adjustment was made for 
multiple comparison testing other than Dunnett’s. 95% 
CIs of the effect are displayed where appropriate. GraphPad 
Prism 7 statistical software v7.02 (GraphPad Software, Inc) 
was used with P < 0.05 considered statistically significant. 
A multivariable linear regression model was fitted to 
4- and 10-week treatment data using both dosage (4.5, 
20 and 60 μg retinyl acetate/g chow) and duration (4 and 
10 weeks) of treatment as independent variables, and bone 
mineral content (BMC), cortical thickness and periosteal 
and endocortical circumference as dependent variable in 
each model. The interaction between dosage and duration 
was used as an additional independent variable. In a 
linear regression model, the association between dosage 
(4.5, 20 and 60 µg/g) and cortical bone mass is linear and 
the model cannot detect a non-linear association, i.e. the 
reported decrease of cortical bone mass per 10 µg/g increase 
is estimated from the overall association between cortical 
bone mass and the dosage in the three treatment groups.
Results
Vitamin A-treated mice appear healthy with 
increased relative liver weights and increased serum 
retinol and retinyl ester levels
After 4 and 10  weeks of treatment with UTL or 
supplemented doses of vitamin A, mice appeared 
healthy with no significant difference in body weight 
change between treatment groups and control (Table  1 
and Supplementary Fig.  1). Liver weight, as percentage 
of body weight, was increased at 4 and 10 weeks in the 
supplemented dose group compared to control mice 
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(Table  1). Bone length of the tibia and femur was not 
significantly affected by the UTL or supplemental doses 
compared to controls (Table 1).
Mice fed control chow containing 4.5 µg retinyl 
acetate/g chow for 4  weeks had serum levels of 
0.84 ± 0.03 µM retinol and 65 ± 17 nM retinyl esters, which 
is similar to what has been previously observed in C57BL/6 
mice (Obrochta et al. 2014). Serum retinol was increased 
significantly by the supplemented dose of vitamin A in 
comparison to control at both time points, with the UTL 
diet showing no significant change (Fig.  1). The serum 
RE (the sum of retinyl linoleate, retinyl palmitate, retinyl 
oleate, retinyl stearate) levels were significantly higher 
than the RE in mice fed control chow after both 4 and 
10 weeks of supplemental vitamin A diet. Mice fed UTL 
chow displayed significantly increased serum RE levels at 
10 weeks (Fig. 1).
Vitamin A decreases cortical bone parameters in a 
time-dependent manner
After 4  weeks of supplemental vitamin A diet, cortical 
BMC, cortical thickness and cortical bone mineral 
density (BMD) were lower in the tibia (Fig.  2A, B and 
C) as assessed by pQCT. After 10  weeks of treatment, 
the effects on cortical BMC were significantly more 
pronounced (Fig.  2A). Both periosteal and endocortical 
circumferences were significantly decreased after 4 weeks 
with the supplemented diet (Fig. 2D and E). The decrease 
in periosteal circumference progressively increased after 
10  weeks (Fig.  2D). Similar results were also obtained 
in the femur (Supplementary Fig. 2A, B, C, D, E and F). 
The UTL diet caused a significant decrease in periosteal 
circumference in both the tibia (Fig. 2D) and the femur 
(Supplementary Fig. 2F) over time.
These changes in cortical bone led to a significant 
decrease in mean polar moment of inertia (predicted 
strength) assessed by pQCT, in both the tibia (Fig. 2F) and 
the femur (Supplementary Fig. 2F) after 4 and 10 weeks 
of treatment with the supplemented diet, but not the 
UTL diet. Formal strength testing (three-point bending) 
Table 1 Final body weight, relative liver weight, femur and tibia length.
4 weeks (n = 15/group) 10 weeks (n = 10/group)
Final body weight (g)
 Control 18.2 ± 0.3 20.9 ± 0.5
 UTL 18.6 ± 0.3 20.2 ± 0.5
 Supplemented 18.2 ± 0.3 20.7 ± 0.5
Liver weight (%)
 Control 4.3 ± 0.09 4.2 ± 0.06
 UTL 4.6 ± 0.07 4.5 ± 0.07
 Supplemented 4.8 ± 0.13** 4.6 ± 0.12**
Tibia length (mm)
 Control 16.8 ± 0.1 17.3 ± 0.15
 UTL 16.9 ± 0.08 17.3 ± 0.19
 Supplemented 16.9 ± 0.13 17.6± 0.17
Femur length (mm)
 Control 14.4 ± 0.11 14.8 ± 0.17
 UTL 14.6 ± 0.09 14.9 ± 0.15
 Supplemented 14.5 ± 0.1 15.0 ± 0.12
Final body weight, liver weight (% of body weight) and tibia and femur length after 4 and 10 weeks of UTL and supplemented diets. Values given as 
mean ± s.e.m.
**P < 0.01: 1-way ANOVA followed by Dunnett’s multiple comparison test vs respective control.
Figure 1
Vitamin A supplementation increases serum retinol and retinyl ester (RE) 
levels. Serum retinol and RE at 4 (A) and 10 (B) weeks. Values given as 
mean ± s.e.m. (n = 10/group). 1-way ANOVA followed by Dunnett’s multiple 
comparison test vs control, *P < 0.05, **P < 0.01, ***P < 0.001.
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was performed on tibias from 10-week supplemental diet, 
since the phenotype observed was more pronounced 
than at 4 weeks. Supplemented vitamin A diet resulted in 
a trend of lower bone strength (−9%; P = 0.055; Fig. 2G), 
while the stiffness remained unchanged between the two 
groups (Fig. 2H).
Linear regression analyses, using data from the three 
treatment groups (4.5, 20 and 60 µg retinyl acetate/g 
chow) and both treatment time points (4 and 10 weeks), 
showed that femur cortical BMC and thickness, as well as 
periosteal and endocortical circumference are significantly 
associated with the dosage of vitamin A when the data 
are adjusted for treatment time (Table 2). There was no 
statistical significant interaction between dosage and time 
for any cortical bone parameter (P > 0.14).
Supplemental vitamin A diet does not affect 
trabecular bone
Trabecular bone mass in tibia was not significantly 
changed after 4 and 10 weeks of UTL and supplemented 
vitamin A chow compared to control, as assessed by 
pQCT (Table  3). To further analyze trabecular bone, 
microCT analysis was performed on the L5 vertebra. 
Results demonstrated that trabecular bone volume 
fraction in the vertebrae was not significantly affected 
with the supplemented vitamin A diet compared to 
control in the present study (Table 3).
Expression analysis of osteoclastic and osteoblastic 
genes in cortical bone
The mRNA expression of osteoclastic genes in cortical 
bone of the tibia (Acp5, Ctsk, Tnfrsf11a, Tnfsf11, Tnfrsf11b) 
was not affected after 4 or 10  weeks of supplemented 
diet (Table  4). At 4  weeks, the mRNA expression of the 
osteoblastic genes osteocalcin (Bglap) and alkaline 
phosphatase (Alpl) were decreased after both supplemented 
(Table 4) and UTL (data not shown) dosages of vitamin A, 
whereas other osteoblastic genes, such as Col1a1, Runx2, 
and Sp7, were not significantly regulated.
In vertebra, the mRNA expression of Acp5, Ctsk, 
Tnfrsf11a, Tnfsf11, Tnfrsf11b, Bglap, Alpl, Col1a, Runx2 and 
Sp7 were not significantly regulated by the supplemented 
diet group after 10 weeks (data not shown).
Figure 2
Supplemented vitamin A dose, but not UTL dose, affects cortical bone 
parameters of the tibia in a time-dependent manner and decreases 
predicted bone strength. UTL and supplemented diet effect on (A) 
cortical bone mineral content (BMC), (B) cortical thickness, (C) cortical 
bone mineral density (BMD), (D) periosteal circumference, (E) 
endocortical circumference, and (F) polar moment of inertia of the tibia. 
pQCT results in % difference vs respective control. Three-point bending 
of the tibia after 10 weeks of supplemented diet (G) maximum load 
applied till failure (P = 0.055) and (H) stiffness. (A, B, C, D, E and F) 
Student’s t-test vs respective controls, *P < 0.05, **P < 0.01, ***P < 0.001. 
2-way ANOVA for interaction, #P < 0.05, ##P < 0.01. n = 15/group at 4 weeks, 
n = 10/group at 10 weeks. (G and H) Student’s t-test, n = 10/group. All 
values displayed as mean ± s.e.m.
Table 2 Linear regression analysis indicates that increases of vitamin A in the chow is significantly associated with lower cortical 
bone parameters when adjusted for number of weeks of treatment.
Change per 10 µg/g increase in dose (95% CI)
Cortical BMC (mg/mm) −0.016 (−0.023, −0.0085)***
Cortical thickness (µm) −0.0012 (−0.0023, −0.0001)*
Periosteal circumference (mm) −0.040 (−0.053, −0.026)***
Endocortical circumference (mm) −0.032 (−0.047, −0.017)***
Values given as change per 10 µg/g increase in dose with 95% confidence intervals (95% CI).
*P < 0.05, ***P < 0.001.
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Serum resorption and formation markers indicate no 
effect on osteoclast or osteoblast activity
Analysis of serum TRAP5b and CTX indicated no 
significant differences in osteoclast activity at 4 or 
10 weeks of supplemented vitamin A diet (Supplementary 
Table  1). Osteoblast activity also appeared to be 
unchanged when analyzed by serum levels of osteocalcin 
(Supplementary Table 1).
Histomorphometric analysis indicates no significant 
change in the number of osteoclasts
TRAP stained longitudinal sections of the femurs of mice 
exposed to supplemented diet for 10 weeks revealed no 
significant change in the number of osteoclasts present 
on either the periosteal, endocortical, or trabecular bone 
(Supplementary Table 2).
Dynamic histomorphometry shows that long-term 
vitamin A transiently increases endocortical bone 
formation rate with no effect on the periosteal 
surface
Dynamic histomorphometry measurements showed that 
endocortical MAR and bone formation rate (BFR/BS) were 
increased in the femur after 4  weeks of supplemented 
diet, but no significant effect on mineralization surfaces 
(MS/BS) was noted in the present study (Table  5). After 
10  weeks of the diet, these increases were no longer 
observed; however, marrow area was decreased by 31% 
compared to controls (Table 5). In contrast, MS/BS, MAR 
or BFR/BS at the periosteal surface were not significantly 
affected at 4 and 10 weeks, although the total area was 
decreased by 19% after 10 weeks (Table 5).
Short duration supplemented and hypervitaminosis 
A diet decrease cortical bone parameters
We observed that the periosteal and endocortical 
circumferences, as well as cortical BMC, were reduced 
after 8  days in mice fed supplemented vitamin A diet 
when assessed by pQCT (Table 6).
Hypervitaminosis A treatment (450 µg retinyl 
acetate/g chow) induced a much larger effect on bone 
phenotype than those observed with supplemented 
diet, illustrated by more pronounced decreases in 
several cortical bone parameters in the femur, including 
cortical BMC and cortical thickness, as well as periosteal 
and endocortical circumferences, without effects on 
longitudinal bone growth (Table 6). We could not detect 
any significant effect on the trabecular BMD (95% CI of 
effect: −78.8, 23.2) in the metaphyseal area of the femur, 
as assessed by pQCT, by hypervitaminosis A diet (Table 6). 
Similar cortical and trabecular parameters were also 
observed in the tibia (data not shown). Mice treated with 
the hypervitaminosis A diet had decreased final body 
weight and increased relative liver weight compared to 
control (Table 6).
Short duration hypervitaminosis A increases the 
number of periosteal osteoclasts and decreases 
endocortical osteoclasts
Static histomorphometry of femurs in mice fed a 
hypervitaminosis A diet showed increases in the number 
of osteoclasts on periosteal bone and decreases on 
endocortical bone, but no effect on trabecular osteoclast 
numbers (Fig. 3A, B, C, D and E). In contrast, no significant 
changes in osteoclast numbers were observed in mice fed 
the supplemented vitamin A diet (Fig. 3C, D and E).
Table 3 UTL and supplemental vitamin A diets did not affect trabecular bone.
Tibia Vertebra
Tb.BMD BV/TV Tb.N Tb.Th Tb.Sp
4 weeks (n = 15/group) (n = 10/group)
 Control 209 ± 6 22.8 ± 1.1 4.96 ± 0.2 46 ± 1 93 ± 3
 UTL 211 ± 6 (−20.7, 24.6) – – – –
 Supplemented 219 ± 9 (−12.1, 33.2) 23.3 ± 1.2 (−2.91, 3.75) 5.22 ± 0.2 (−0.33, 0.85) 45 ± 1 (−4.02, 0.96) 96 ± 4 (−7.94, 13.4)
10 weeks (n = 10/group) (n = 10/group)
 Control 200 ± 8 22.1 ± 1.0 4.77 ± 0.2 47 ± 0.7 158 ± 4
 UTL 210 ± 12 (−26.3, 45.0) – – – –
 Supplemented 179 ± 12 (−56.5, 14.8) 22.4 ± 1.4 (−3.37, 3.79) 5.02 ± 0.3 (−0.53, 1.04) 45 ± 1 (−4.54, 0.43) 155 ± 5 (−16.2, 10.2)
Trabecular bone mineral density (Tb. BMD; mg/cm3), as analyzed by pQCT, in tibia at 4 and 10 weeks of UTL and supplemented vitamin A diet. Vertebral 
bone volume/tissue volume (BV/TV; %), trabecular number (Tb.N; /mm), thickness (Tb.Th; µm) and separation (Tb.Sp; µm) of the L5 vertebra via µCT after 
4 and 10 weeks of supplemented vitamin A treatment and the 95% CI of the effect in brackets. Values are given as mean ± s.e.m. 1-way ANOVA followed 
by Dunnett’s multiple comparison test vs control for tibia pQCT and Student’s t-test vs control for µCT of vertebra.
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Short duration hypervitaminosis A increases 
osteoclastic gene expression and serum Trap5b
Cortical bone gene expression in tibia of the 
osteoclast genes Acp5, Ctsk and Tnfsf11 increased with 
hypervitaminosis A treatment compared to control, but 
was not significantly changed by supplemental vitamin A 
diet compared to control (Fig.  3F, G and H). This 
stimulatory effect by hypervitaminosis A was mimicked 
by serum TRAP5b analysis (Fig. 3N).
Short-term supplemented dose of vitamin A affects 
periosteal and endocortical bone formation
Osteoblast genes (Tnfrsf11b, Alpl, Bglap, Runx2 and Sp7) 
remained unchanged with both the supplemented dose 
and hypervitaminosis A treatment (Fig.  3I, J, K, L and 
M). Importantly, dynamic histomorphometry in mice 
fed the supplemented vitamin A diet for 8 days showed 
a pronounced decrease in periosteal BFR (−61%, P < 0.05; 
Table 7). In contrast, endocortical BFR was increased by 
the supplemented diet (Table 7).
Vitamin A effects on cortical bone were not 
observed in the presence of bisphosphonate 
treatment
No significant effects of vitamin A on periosteal or 
endocortical circumferences was observed when ZA-treated 
mice were fed supplemented vitamin A chow (Fig. 4D and 
E). Treatment with ZA resulted in decreased bone length 
(Fig.  4A) and increased trabecular BMD and cortical 
thickness (Fig.  4B and C) compared to vehicle controls. 
Mice treated with ZA appeared healthy throughout the 
experiment and the treatment did not affect body weight 
change (Supplementary Fig. 1C).
Discussion
The main findings of this study are as follows: 
(1) Experiments of 10-week duration with diets containing 
either 20 or 60 µg retinyl acetate/g of chow resulted in 
dose-dependent increases of circulating levels of RE equal 
to 130 and 231 nM, respectively. These are levels below 
or close to levels suggested for hypervitaminosis A in 
humans (200 nM) (Krasinski et  al. 1989). (2) Increases 
in vitamin A levels time-dependently decreased cortical 
bone mass resulting in a trend toward decreased strength, 
(3) supplemental vitamin A diet did not significantly 
affect trabecular bone phenotype in the tibia or vertebra, 
(4) increased osteoclastic bone resorption, in combination 
with an early decrease in periosteal bone formation 
resulted in decreased periosteal circumference and (5) 
enhanced endocortical bone formation resulted in 
decreased marrow area and endocortical circumference.
The predominant form of vitamin A in the serum 
is retinol with normal physiological levels of 2–4 µM 
in humans and 1 µM in mice (Krasinski et  al. 1989, 
Michaelsson et  al. 2003, O’Byrne & Blaner 2013, 
Obrochta et al. 2014). In the present study, mice fed the 
supplemental diet had increased serum retinol levels. This 
method of determining vitamin A status is frequently 
used in human assessment; however, retinol levels in the 
serum are not reflective of vitamin A status unless there 
is a deficiency or surplus of the nutrient. Serum retinyl 
Table 4 Expression analysis of osteoclastic and osteoblastic genes in cortical bone after 4 and 10 weeks of supplemented 
vitamin A diet.
4 week
CI of effect
10 week
CI of effectControl Supplemented Control Supplemented
Acp5 (Trap) 1.00 ± 0.16 0.78 ± 0.07 −0.58, 0.14 1.00 ± 0.10 0.89 ± 0.08 −0.38, 0.17
Ctsk 1.00 ± 0.17 0.81 ± 0.08 −0.59, 0.21 1.00 ± 0.11 0.83 ± 0.06 −0.44, 0.09
Tnfrsf11a (Rank) 1.00 ± 0.12 0.97 ± 0.09 −0.35, 0.29 1.00 ± 0.10 0.90 ± 0.05 −0.34, 0.14
Tnfsf11 (Rankl) 1.00 ± 0.17 0.90 ± 0.07 −0.49, 0.29 1.00 ± 0.13 1.03 ± 0.13 −0.35, 0.42
Tnfrsf11b (Opg) 1.00 ± 0.20 0.79 ± 0.12 −0.69, 0.27 1.00 ± 0.06 1.39 ± 0.19 −0.03, 0.82
Bglap (Ocn) 1.00 ± 0.18 0.49 ± 0.08* −0.93, −0.09 1.00 ± 0.10 1.05 ± 0.18 −0.37, 0.48
Alpl 1.00 ± 0.15 0.63 ± 0.06* −0.70, −0.04 1.00 ± 0.07 1.13 ± 0.17 −0.25, 0.51
Col1α1 1.00 ± 0.17 0.82 ± 0.07 −0.57, 0.21 1.00 ± 0.10 1.10 ± 0.17 −0.31, 0.52
Runx2 1.00 ± 0.20 0.60 ± 0.07 −0.84, 0.04 1.00 ± 0.07 1.06 ± 0.06 −0.14, 0.25
Sp7 (Osterix) 1.00 ± 0.13 1.35 ± 0.20 −0.14, 0.85 1.00 ± 0.06 1.18 ± 0.11 −0.09, 0.45
Osteoclastic (Acp5, Ctsk, Tnfrsf11a, Tnfsf11, and Tnfrsf11b) and osteoblastic (Bglap, Alpl, Col1α1, Runx2, and Sp7) genes at 4 and 10 weeks of 
supplemented vitamin A treatment and the 95% CI of the effect. Data is displayed as fold change relative to control, n = 10/group, mean ± s.e.m., 
Student’s t-test vs control.
*P < 0.05.
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esters have been shown to be a more precise measurement 
of vitamin A status (Croquet et  al. 2000). The normal 
physiological levels of retinyl esters in humans are in 
the range of 50–200 nM (Krasinski et  al. 1989, Ballew 
et  al. 2001), and it has been suggested that RE levels 
over 200 nM or exceeding 10% of total serum vitamin A 
(retinol and RE) may indicate excess vitamin A stores 
and potential vitamin A toxicity (Krasinski et  al. 1989), 
although a specific cutoff has been difficult to determine 
(Ballew et al. 2001). In our experiments, 4 and 10 weeks 
of supplemented vitamin A diet resulted in RE levels of 
343 ± 65 nM and 231 ± 21 nM, respectively, which exceeds 
the suggested RE threshold set for humans and indicates 
potential vitamin A excess.
The UTL dose used in the present study (20 µg retinyl 
acetate/g chow) resulted in RE levels of 130–143 nM at 4 
and 10 weeks. This dose, modeled after the human UTL, 
by definition should be the maximum vitamin A 
consumption that does not cause ill effects. Although 
no statistically significant bone phenotype compared to 
control was observed, there was a trend for effects on 
all cortical bone parameters observed after 10, but not 
after 4 weeks, which is reflected by a significant decrease 
of periosteal circumference in the femur and tibia at 
10 weeks when compared to the circumference at 4 weeks. 
The effects at 10 weeks were also similar, though not as 
pronounced as those noted with the supplemented diet 
(60 µg retinyl acetate/g chow) at 10 weeks.
Linear regression analysis showed that there was a 
significant association of increased vitamin A dosage 
(4.5, 20 and 60 µg retinyl acetate/g chow) and decreased 
cortical bone parameters. These observations indicate that 
even small increases of the vitamin A dose may negatively 
affect cortical bone parameters although the effects of the 
Table 5 Dynamic histology shows vitamin A transiently increases endocortical bone formation after 4 weeks of supplemented 
vitamin A diet. Histological analysis indicates smaller marrow area and total area after 10 weeks of supplemental diet.
4 weeks 10 weeks
InteractionControl Supplemented Control Supplemented
Periosteal
 MS/BS (%) 30.5 ± 2.27 22.0 ± 3.44 31.2 ± 3.85 29.2 ± 1.81 n.s.
 MAR (µm/day) 0.72 ± 0.06 0.59 ± 0.07 0.67 ± 0.04 0.64 ± 0.07 n.s.
 BFR/BS (µm3/µm2/day) 0.22 ± 0.03 0.19 ± 0.06 0.23 ± 0.04 0.19 ± 0.02 n.s.
Endocortical
 MS/BS (%) 76.4 ± 1.40 81.2 ± 2.83 74.0 ± 3.20 81.4 ± 3.38 n.s.
 MAR (µm/day) 2.18 ± 0.20 2.82 ± 0.10* 1.38 ± 0.05 1.39 ± 0.11 P < 0.05
 BFR/BS (µm3/µm2/day) 1.66 ± 0.15 2.28 ± 0.08** 1.02 ± 0.05 1.16 ± 0.11 P < 0.05
Ma.Ar (mm2) 0.52 ± 0.03 0.55 ± 0.03 0.74 ± 0.03 0.51 ± 0.03*** P < 0.001
Tt.Ar (mm2) 0.96 ± 0.04 0.96 ± 0.04 1.48 ± 0.05 1.2 ± 0.03*** P < 0.01
Ct.Ar (mm2) 0.44 ± 0.01 0.41 ± 0.01 0.74 ± 0.03 0.69 ± 0.01 n.s.
Femur periosteal and endocortical mineralized surface/bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate/bone surface  
(BFR/BS) obtained from dynamic histomorphometry, and marrow area (Ma.Ar), total area (Tt.Ar), and cortical bone area (Ct.Ar) after 4 and 10 weeks of 
supplemented vitamin A diet. Values represented as mean ± s.e.m., n = 10/group, Student’s t-test vs control, 2-way ANOVA for interactions, n.s. indicates 
no statistical significance.
*P < 0.05, **P < 0.01, ***P < 0.001.
Table 6 Short duration supplemented vitamin A diet decreased endocortical circumference and hypervitaminosis A diet 
decreased cortical bone parameters.
Control Supplemented Hypervitaminosis A
Final body weight (g) 18.6 ± 0.3 18.1 ± 0.2 17.3 ± 0.2**
Liver weight (%) 4.9 ± 0.1 4.9 ± 0.09 5.3 ± 0.1**
Femoral length (mm) 14.2 ± 0.07 14.2 ± 0.05 14.3 ± 0.07
Tb. BMD (mg/cm3) 387.8 ± 9.83 347.3 ± 17.3 360.0 ± 15.5
Endocortical circumference (mm) 3.28 ± 0.03 3.16 ± 0.02** 3.07 ± 0.03***
Periosteal circumference (mm) 4.94 ± 0.03 4.81 ± 0.03** 4.51 ± 0.03***
Cortical BMC (mg/mm) 0.86 ± 0.01 0.83 ± 0.01* 0.64 ± 0.02***
Cortical thickness (µm) 264 ± 3 262 ± 2 229 ± 5***
Final body and relative liver weight, femoral length, trabecular bone mineral density (Tb. BMD), endocortical and periosteal circumferences, cortical 
bone mineral content (BMC), and cortical thickness as assessed by pQCT of the femur after 8 days of supplemented and hypervitaminosis A diet. Values 
represented as mean ± s.e.m., n = 10/group, 1-way ANOVA followed by Dunnett’s multiple comparison test vs control.
*P < 0.05, **P < 0.01, ***P < 0.001.
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UTL dose, when tested separately, did not reach statistical 
significance.
Supplemented vitamin A diet caused a decrease in 
periosteal and endocortical circumferences of bone after 
8 days, and at 4 and 10 weeks, with the severity of the 
periosteal phenotype increasing with time. Cortical BMC 
also mimicked this effect. These findings are consistent 
with previous studies, regardless of doses, administration 
or animal model used (Johansson et al. 2002, Kneissel et al. 
2005, Lind et  al. 2006, 2011, 2013). Cortical thickness 
significantly decreased after 10  weeks of supplemented 
vitamin A diet in the present study, and collectively, the 
results of our study indicate smaller bones.
In human studies, associations have been made 
between elevated vitamin A intake and decreased bone 
strength (Melhus et  al. 1998, Feskanich et  al. 2002, 
Promislow et al. 2002, Michaelsson et al. 2003); however, 
it is important to note that not all studies have observed 
this and on the contrary, inverse (Barker et  al. 2005, 
Maggio et al. 2006) or no (Sowers & Wallace 1990, Wolf 
et al. 2005) association between increased vitamin A intake 
and fracture risk have also been reported. A meta-analysis 
of 12 prospective studies has recently concluded that 
both high and low levels of serum retinol, but not intake 
of β-carotene, are associated with increased risk of hip 
fracture, but not the risk of all fractures in the skeleton 
(Wu et al. 2014). These findings are in agreement with our 
observations that increased vitamin A decreases cortical 
but not trabecular bone. Johansson et  al. investigated 
‘subclinical hypervitaminosis A’ doses in rats and observed 
that 180 µg retinyl acetate and palmitate/g pellet for 
12 weeks resulted in a significant reduction of breaking 
force compared to controls (Johansson et  al. 2002). 
A short-duration (7-day) hypervitaminosis A (510 µg 
retinyl acetate and palmitate/g pellet) study in rats done 
by Lind et al. also observed a reduction in bone strength 
(Lind et  al. 2011). These data, along with our findings, 
indicate weaker bones with increased vitamin A intake, 
even at clinically relevant doses although a certain 
threshold of vitamin A status most likely must be reached. 
Our supplemented vitamin A dose (60 µg retinyl acetate/g 
chow) resulted in reduced bone strength calculated 
indirectly as polar moment of inertia from pQCT data. 
Three-point bending also indicated a trend in reduced 
bone strength (−9%) after 10 weeks; however, it was not 
statistically significant.
While a cortical phenotype is evident, both with 
our clinically relevant doses of vitamin A-treated mice, 
and previous rat hypervitaminosis A studies, fewer 
studies have addressed the trabecular bone phenotype. 
Figure 3
Short duration hypervitaminosis A experiment decreased cortical bone 
parameters, an effect caused by an increase in osteoclast number. 
Representative images of TRAP stained sections of femur of (A) control 
and (B) hypervitaminosis A treated mice for 8 days, scale bars represent 
100 µm. Osteoclast numbers per measured bone surface counted from 
the (C) periosteum, (D) endosteum, and (E) trabeculae in TRAP stained 
femur sections of control (n = 10), supplemental (n = 9), and 
hypervitaminosis A (n = 5) mice after 8 days. Gene expression from 
cortical bone of the tibia of osteoclastic genes (F) Acp5 (encodes for 
Trap), (G) Ctsk, (H) Tnfsf11 (encodes for Rankl), (I) Tnfrsf11b (encodes 
for Opg) and osteoblastic genes (J) Alpl, (K) Bglap (encodes for 
Osteocalcin), (L) Runx2, and (M) Sp7 (encodes for Osterix) in fold 
change relative to control. Serum analysis of (N) TRAP5b. Figures 
displayed as mean ± s.e.m., 1-way ANOVA followed by Dunnett’s  
multiple comparison test vs control, *P < 0.05, **P < 0.01, ***P < 0.001, 
n = 10/group.
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Kneissel et al. injected rats with 150 µg/kg of retinoid (Ro 
13-6298) once per day for 4 days and found no changes 
in tibia trabecular BMD based on pQCT (Kneissel et  al. 
2005). Green et al. gavage-fed mice with ATRA (5 mg/kg/
day) for 10 days and did not observe changes in trabecular 
bone volume of the tibia assessed by histomorphometric 
analysis (Green et  al. 2015). On the other hand, Lind 
et  al. observed a statistically significant decrease in 
femur trabecular BMD when rats were fed excess vitamin 
A (510 µg retinyl acetate and palmitate/g pellet) for 
7  days (Lind et  al. 2011), and Wray et  al. also observed 
lower trabecular BMD of the tibia in rats fed adequate 
(4 µg retinyl palmitate/g chow) and supplemented (50 µg/g) 
vitamin A diets compared to marginal (0.35 µg/g) vitamin 
A diet from weaning to 2–3, 8–10 and 18–20 months of 
age (Wray et  al. 2011). Likewise, C57BL/6 female mice 
fed a diet of 22.5 µg retinol/g of chow from weaning to 
6 months of age had significantly reduced BV/TV in the 
vertebra, as demonstrated by Yorgan et  al. (2016). This 
conflicting evidence of excess vitamin A on trabecular 
bone may partially be explained by administration, 
dosage, duration, gender and age differences of the rodents 
used in these investigations, but the effect of vitamin A on 
trabecular bone remains an area that has been relatively 
unexplored. We were unable to detect any effect on 
trabecular bone in the tibia or vertebra of female mice 
at 4 or 10 weeks using doses of vitamin A that decreased 
cortical bone mass, and our hypervitaminosis A dose did 
not significantly alter trabecular bone after 8 days.
A mechanism for the decrease in bone size was not 
elucidated by gene expression analysis on cortical bone 
or serum turnover markers. In agreement with these 
observations, the number of periosteal, endocortical 
and trabecular osteoclasts in the present study was not 
significantly affected with supplemented vitamin A diet. 
Kneissel et al. gave rats subcutaneous injections of 125 µg/kg 
of retinoid (Ro 13-6298) daily for 4 days. This caused an 
increase in serum TRAP5b levels due to increased periosteal 
osteoclast numbers (Kneissel et  al. 2005). Lind et  al. fed 
rats 510 µg retinyl acetate and palmitate/g pellet for 7 days 
and also found that a hypervitaminosis A dose increased 
the number of periosteal osteoclasts. In contrast to 
Kneissel et al., Lind et al. observed that hypervitaminosis A 
decreased serum TRAP5b and CTX, possibly due to the 
reduced number of endocortical osteoclasts found in their 
study (Lind et al. 2011). Confirming the previous studies 
in rats (Kneissel et al. 2005, Lind et al. 2011), we found 
that short-term hypervitaminosis A in mice substantially 
Table 7 Dynamic histology shows vitamin A decreased periosteal bone formation and increased endocortical bone formation 
after 8 days of supplemented vitamin A diet.
Control (n = 10) Supplemented (n = 8)
Periosteal
 MS/BS (%) 23.2 ± 4.34 18.1 ± 3.98
 MAR (µm/day) 2.16 ± 0.55 0.91 ± 0.11P = 0.062
 BFR/BS (µm3/µm2/day) 0.47 ± 0.10 0.18 ± 0.06*
Endocortical
 MS/BS (%) 85.7 ± 2.4 88.3 ± 1.8
 MAR (µm/day) 5.38 ± 0.26 6.50 ± 0.31*
 BFR/BS (µm3/µm2/day) 4.63 ± 0.30 5.76 ± 0.36*
Femur periosteal and endocortical mineralized surface/bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate/bone surface  
(BFR/BS) after 8 days of supplemented vitamin A diet obtained from dynamic histomorphometry. Values represented as mean ± s.e.m. Student’s t-test.
*P < 0.05.
Figure 4
Vitamin A effects on cortical bone were not observed in the presence of bisphosphonate treatment. Femur (A) length, (B) trabecular bone mineral density 
(Tb. BMD), (C) cortical bone thickness, and (D) periosteal and (E) endocortical circumference as measured by pQCT. Similar results observed in tibia. Values 
given as mean ± s.e.m., n = 10/group. Student’s t-test; Vehicle (VEH): control vs supplemented, and Zoledronic acid (ZA): control vs supplemented *P < 0.05, 
**P < 0.01. Student’s t-test ZA treatment vs respective VEH control, #P < 0.05, ##P < 0.01, ###P < 0.001. 2-way ANOVA for interaction, P > 0.05.
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increased osteoclast numbers on the periosteal surface of 
the long bones and increased serum Trap5b. The enhanced 
number of osteoclasts was associated with an increased 
expression of the genes encoding TRAP and cathepsin K 
due to the increased expression of the RANKL gene. This 
is in agreement with our previous ex vivo observations in 
vitamin A-treated mouse calvarial bones (Conaway et al. 
2011). Similar to Lind et al., we also observed that short 
term hypervitaminosis A, for reasons unknown, decreased 
endocortical osteoclast numbers.
Based on periosteal MS/BS in the femur and tibia of rats, 
studies have suggested that the number of active osteoblasts 
is decreased in hypervitaminosis A treatment (Kneissel et al. 
2005, Lind et al. 2013). In one of these studies (Lind et al. 
2013), a strong decrease of osteoblastic bone formation 
was seen in rats fed 510 µg retinyl acetate and palmitate/g 
pellet for 7 days. This resulted in a decrease in MAR and 
BFR in the periosteal bone of the femur. In another study 
(Kneissel et al. 2005), no decrease of MAR, but a decrease 
of MS was observed in rats given subcutaneous injections 
of Ro 13-6298. In the present study, we observed that the 
supplemental dose of vitamin A in mice also decreased 
periosteal bone formation at 8  days. In contrast to the 
observations in the periosteum, treatment with vitamin A 
for 8 days enhanced bone formation at the endocortical 
surface, with no change in MS/BS, suggesting increased 
osteoblast activity. Transient loss of this effect may indicate 
a new steady state in bone remodeling.
Altogether, our observations suggest that reduced 
periosteal circumference caused by vitamin A may be due 
to both increased bone resorption and decreased formation 
and that the reduced endocortical circumference may 
be due to both enhanced bone formation and reduced 
resorption. To elucidate the mechanism involved in 
the cortical bone phenotype in the present study, we 
used a bisphosphonate, ZA. Treating mice with ZA or a 
saline vehicle and supplemented or control vitamin A 
diets indicated that the effect of vitamin A on the 
amount of cortical bone seems to be primarily mediated 
by osteoclasts, because there was no effect on cortical 
bone parameters in mice fed vitamin A and treated with 
ZA. Our observations further suggest that the decreased 
periosteal bone formation and increased endocortical 
bone formation that were observed may be secondary to 
an effect of vitamin A on osteoclasts, but we cannot rule 
out the possibility that direct effects on bone formation 
are too small in magnitude to result in significant effects 
on cortical bone mass.
The present study was conducted in female mice, 
and since gender differences have been reported in 
age-related bone loss in mice (Glatt et al. 2007), our results 
may not necessarily be transferable to male mice. For the 
present study, we used young mice that were growing for 
the first 5–6 weeks of vitamin A dietary consumption. It 
is possible that the effects observed are a combination of 
bone growth and adult bone remodeling. However, we 
did not observe any vitamin A effects on bone length 
measurements. Although bone remodeling in growing 
mice may not be identical to bone remodeling in adult 
humans, our observations support the epidemiological 
findings in humans indicating that vitamin A is a risk 
factor for osteoporosis and further suggest that the UTL 
in humans may need to be re-evaluated in relation to the 
harmful effects on the skeleton.
Conclusion
Our results suggest that even clinically relevant doses 
of vitamin A consumed over a long period of time may 
have a negative impact on bone phenotype, mainly on 
cortical bone, with trabecular bone remaining unaffected. 
These data might help to explain why increased vitamin A 
intake and enhanced serum retinol appear to be associated 
with an increased risk of non-vertebral fractures, mainly 
dependent on cortical bone, but not with risk of vertebral 
fractures, mainly dependent on trabecular bone.
Supplementary data
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